← Back to Search

Psychostimulant

Low vs. Normal Dose Psychostimulants for ADHD

Phase 1 & 2

Waitlist Available

Led By Adele Diamond, Ph.D.

Research Sponsored by University of British Columbia

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Between the chronological ages of 6 and 18 years

Currently treated with and responding to oral Psychostimulants >= 20 mg/day and not on a "drug holiday"

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 weeks

Awards & highlights

Study Summary

This trial will compare the cognitive performance of children with ADHD who are taking a lower dose of psychostimulants to those taking a moderate to high dose of psychostimulants.

Who is the study for?

Children aged 6-18 with ADHD, either combined or inattentive type, who are stable on a psychostimulant dose of at least 20 mg/day. They must have an IQ above 90 and be able to perform simple tasks and communicate in English. Excluded are those with severe reactions to lower doses of medication, certain mental health conditions, below-average IQ, major sensory impairments, or other medications affecting cognitive skills.Check my eligibility

What is being tested?

The study tests if children with ADHD perform better cognitively on a low-dose (half their current dose) versus their normal dose of psychostimulants. It's a double-blind crossover trial where neither the participants nor the researchers know which dosage is being administered first.See study design

What are the potential side effects?

While not explicitly stated here, common side effects of psychostimulants can include decreased appetite, sleep problems, increased heart rate and blood pressure, stomach pain and headaches.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 6 and 18 years old.

Select...

I am currently taking and responding well to a daily dose of 20 mg or more of oral Psychostimulants without any breaks.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Executive Functions (difference in performance on the two Psychostimulant doses)

Executive Functions (difference in performance on the two Psychostimulants doses)

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: Normal-dose Psychostimulant, Low-doseExperimental Treatment1 Intervention

Normal-dose: Dose participants are currently taking as part of their prescription (on more than or equals to 20 mg/day of Psychostimulants) Low-dose: Half the normal dose

Group II: Low-dose Psychostimulants, Normal-doseActive Control1 Intervention

Normal-dose: Dose participants are currently taking as part of their prescription (on more than or equals to 20 mg/day of Psychostimulants) Low-dose: Half the normal dose

Group III: No intervention, No interventionActive Control1 Intervention

This arm is completely no intervention, and is ONLY for healthy volunteers. We are testing healthy volunteers of the same age to give us an estimate of order effects to help us correct for better performance in the 2nd session due simply to taking the same tests twice (note: the tests are Version A and B).

0 / 2Eligibility criteria met

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

University of British ColumbiaLead Sponsor

1,415 Previous Clinical Trials

2,466,964 Total Patients Enrolled

9 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)

1,572 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)

Adele Diamond, Ph.D.Principal InvestigatorDepartment of Psychiatry, University of British Columbia

Media Library

Psychostimulants (Psychostimulant) Clinical Trial Eligibility Overview. Trial Name: NCT02167048 — Phase 1 & 2

Attention Deficit Hyperactivity Disorder (ADHD) Research Study Groups: Normal-dose Psychostimulant, Low-dose, Low-dose Psychostimulants, Normal-dose, No intervention, No intervention

Attention Deficit Hyperactivity Disorder (ADHD) Clinical Trial 2023: Psychostimulants Highlights & Side Effects. Trial Name: NCT02167048 — Phase 1 & 2

Psychostimulants (Psychostimulant) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02167048 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are patients over the age of 75 years old still able to enroll in this research study?

"According to the eligibility requirements for this study, patients that are eligible to participate in the trial must be aged 6 to 18. There 112 clinical trials currently underway for patients under 18 and 40 for those over 65."

Answered by AI

Is this study currently looking for more participants?

"No, this specific study is not looking for additional patients at the moment. Although, it is worth mentioning that there are many other trials (161 to be exact) that are actively recruiting people right now."

Answered by AI